OncoC4 Announces FDA Approval of IND Application for Best-in-Class PD-1/VEGF Bispecific Antibody AI-081 for the Treatment of Advanced Solid Tumors

 2024-12-04

A Flourishing of Original Innovations

On April 22, 2024, AcroImmune Biopharma announced that its first-in-class Siglec 10 antibody received FDA approval for clinical trials to treat solid tumors. Professors Yang Liu and Pan Zheng, founders of AcroImmune Biopharma, have conducted pioneering work on the CTLA-4 and CD24/Siglec-10 pathways. Their next-generation differentiated CTLA-4 antibody is currently in Phase III clinical trials, and the CD24 antibody has been licensed to Merck & Co.

 2024-09-02

Across the Pacific: Serving Enterprises in Nanjing

On the afternoon of April 19 local time, the China-Nanjing - US-New York Cooperation and Exchange Meeting was held in New York City.

 2024-09-02

District Leader Visits and Surveys AcroImmune

On the morning of March 27th, Lin Tao, the Secretary of the District Committee, conducted a special investigation on technology-based enterprises in the entire district, emphasizing the need to deeply study and implement the important speech of General Secretary Xi Jinping during the deliberation of the Jiangsu delegation ...

 2024-09-02

March 25, 2024, the AcroImmune Innovative Large Molecule Drug R&D Center and the AcroImmune Antibody-Drug Conjugate Innovation Center were inaugurated in the Jiangning Hi-Tech Zone of Nanjing. Han Liming met with Liu Yang, Chairman of AcroImmune.

The unveiling of the innovative macromolecular drug Research and Development center Han Liming met with Liu Yang, chairman of the company

 2024-09-02

Unveiling Ceremony for AcroImmune's Innovative Large Molecule Drug R&D Center; Han Liming Meets with OncoC4 Chairman Liu Yang

On March 25, the "Innovative macromolecular Drug Research and Development Center" of Aoke Immune was unveiled in Nanjing Jiangning High-tech Zone. Party Secretary Han Liming met with Liu Yang, founder and chairman of Anco Immunology.

 2024-09-02

Phase 1b Clinical Trial of Next-Generation CTLA-4 Monoclonal Antibody ONC-392 for Gastrointestinal Solid Tumors Officially Launched at Sun Yat-sen University Cancer Center

On February 9, 2023 in Guangzhou, with the support of President Xu Ruihua and his team of Sun Yat-Sen University Cancer Hospital and close cooperation with partner units, the "ONC-392 Phase 1b clinical study for the treatment of liver cancer, stomach cancer, esophageal cancer and anal canal cancer" clinical trial project launch meeting was successfully held in Sun Yat-sen University Cancer Hospital

 2024-08-25